Transplanted heart made more acceptable by daclizumab

by Medindia Content Team on  July 13, 2005 at 10:46 AM General Health News   - G J E 4
Transplanted heart made more acceptable by daclizumab
Daclizumab has been found to reduce the risk of cellular rejection after a heart transplant when used on top of standard immunosuppression.

The drug, a humanized monoclonal antibody, is directed against the interleukin-2 receptor, thereby inhibiting T-cell proliferation.

Patients who were taken into the Study were either given daclizumab or a placebo.

The primary endpoint was a composite of moderate or severe cellular rejection, hemodynamically significant graft dysfunction, a second transplantation, or death or loss to follow-up within 6 months.

It has been reported 44.7% of patients in the placebo group reached the primary endpoint, versus just 35.6% in the daclizumab group-equivalent to a 25% relative risk reduction with the novel therapy Rejection was also less common with Daclizumab than Placebo. However, six patients receiving daclizumab died from infection when receiving concomitant cytolytic therapy compared with none in the placebo group.

When the negative aspect of daclizumab use is examined, researchers would not be willing to trade even a small increase in the risk of death from infection for a reduction in the risk of histologic rejection.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All